Float Short %

15.46

Margin Of Safety %

Put/Call OI Ratio

0.35

EPS Next Q Diff

0.29

EPS Last/This Y

0.08

EPS This/Next Y

1.85

Price

13.49

Target Price

34.38

Analyst Recom

1.25

Performance Q

17.82

Relative Volume

0.81

Beta

0.82

Ticker: URGN

19 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-06-02	URGN	4.84	0.24	0.60	84123
2025-06-03	URGN	5	0.25	0.17	86054
2025-06-04	URGN	4.91	0.26	3.08	86100
2025-06-05	URGN	5.13	0.28	0.18	87781
2025-06-06	URGN	7.38	0.27	0.26	90129
2025-06-09	URGN	7.04	0.30	1.02	96202
2025-06-10	URGN	7.06	0.33	1.30	100478
2025-06-11	URGN	7.28	0.35	2.39	104566
2025-06-12	URGN	10.98	0.35	0.52	107876
2025-06-13	URGN	12.06	0.39	0.55	111080
2025-06-16	URGN	14.35	0.42	0.85	115199
2025-06-17	URGN	13.24	0.49	1.60	120396
2025-06-18	URGN	14.91	0.48	0.54	120961
2025-06-20	URGN	14.64	0.49	0.15	122406
2025-06-23	URGN	14.32	0.33	0.23	43019
2025-06-24	URGN	13.76	0.32	0.65	43565
2025-06-25	URGN	13.72	0.34	0.05	46879
2025-06-26	URGN	13.1	0.34	0.35	46992
2025-06-27	URGN	13.5	0.35	2.16	47331
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-06-02	URGN	4.84	11.5	-	-2.89
2025-06-03	URGN	5.00	11.5	-	-2.89
2025-06-04	URGN	4.91	11.5	-	-2.89
2025-06-05	URGN	5.14	11.5	-	-2.89
2025-06-06	URGN	7.38	11.5	-	-2.89
2025-06-09	URGN	7.02	11.5	-	-2.89
2025-06-10	URGN	7.05	11.5	-	-2.89
2025-06-11	URGN	7.28	11.5	-	-2.89
2025-06-12	URGN	11.08	11.5	-	-2.89
2025-06-13	URGN	12.03	11.5	-	-2.89
2025-06-16	URGN	14.36	11.3	-	-2.67
2025-06-17	URGN	13.26	11.3	-	-2.67
2025-06-18	URGN	14.87	11.3	-	-2.67
2025-06-20	URGN	14.65	11.3	-	-2.74
2025-06-23	URGN	14.31	10.5	-	-2.74
2025-06-24	URGN	13.78	10.5	-	-2.74
2025-06-25	URGN	13.72	10.5	-	-2.74
2025-06-26	URGN	13.12	10.5	-	-2.74
2025-06-27	URGN	13.49	10.5	-	-2.88
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-06-02	URGN	-0.16	16.94	14.37
2025-06-03	URGN	-0.16	16.94	14.37
2025-06-04	URGN	-0.16	16.94	14.37
2025-06-05	URGN	-0.16	16.94	14.37
2025-06-06	URGN	-0.16	16.94	14.37
2025-06-09	URGN	-0.16	16.92	14.37
2025-06-10	URGN	-0.16	16.92	14.37
2025-06-11	URGN	-0.24	16.92	10.07
2025-06-12	URGN	-0.24	16.92	10.07
2025-06-13	URGN	-0.24	16.92	10.07
2025-06-16	URGN	-0.26	14.35	9.88
2025-06-18	URGN	-0.26	14.35	9.88
2025-06-20	URGN	-0.26	14.35	9.88
2025-06-23	URGN	-0.26	28.62	9.88
2025-06-24	URGN	-0.26	28.62	9.88
2025-06-25	URGN	-0.26	28.62	9.88
2025-06-26	URGN	-0.26	28.62	15.46
2025-06-27	URGN	-0.26	28.62	15.46
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.92

Avg. EPS Est. Current Quarter

-0.83

Avg. EPS Est. Next Quarter

-0.63

Insider Transactions

-0.26

Institutional Transactions

28.62

Beta

0.82

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

52.2

Max Drawdown 5-Year %

-85.4

Target Price

34.38

P/E

Forward P/E

PEG

P/S

6.77

P/B

P/Free Cash Flow

EPS

-3.18

Average EPS Est. Cur. Y

-2.88

EPS Next Y. (Est.)

-1.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-150.68

Relative Volume

0.81

Return on Equity vs Sector %

274.1

Return on Equity vs Industry %

291.9

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

0.01

EBIT Estimation

UroGen Pharma Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 234

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today

news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025

marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance

stock history URGN – UroGen Pharma Ltd. invest stock market

stock prices URGN premarket after hours

ticker URGN fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: URGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y